European shares edged lower on Tuesday, with the benchmark STOXX 600 slipping 0.2%, as rising oil prices revived concerns about persistent inflation and its impact on central bank policy. The decline was compounded by a sharp drop in Swiss pharmaceutical giant Novartis, which fell 8.8% after its experimental drug del-desiran missed its goal in a late-stage trial.
Oil prices and inflation fears
Brent crude, the international oil benchmark, hovered near $98.50 a barrel, a level not seen in months. The climb was driven by geopolitical tensions in the Middle East, after Iran warned it could retaliate against fresh attacks by targeting energy infrastructure across the Gulf, including US oil and gas interests. Such threats raise the specter of supply disruptions in a region that accounts for a significant share of global oil output.
For investors, higher oil prices are more than just a headline risk. Energy costs feed directly into the prices of goods and services, from transportation to manufacturing. When oil rises sharply, it can push inflation higher, making it harder for central banks to cut interest rates as quickly as markets hope. The European Central Bank and other major central banks have been navigating a delicate balance between supporting growth and keeping inflation in check.
"Markets are reading this as a higher chance of sustained energy costs," said one analyst. "That can keep inflation sticky and complicate central banks' plans to ease monetary policy."
Novartis trial setback
Meanwhile, Novartis shares suffered their biggest one-day drop in years after the company announced that del-desiran, an investigational drug for a rare cardiovascular condition, failed to meet its primary endpoint in a late-stage clinical trial. This marks the second consecutive late-stage disappointment for the Swiss drugmaker, following a similar setback earlier in the year.
The news dragged the Swiss market lower and weighed on the broader healthcare sector within the STOXX 600. Pharmaceutical companies often see significant share price swings around clinical trial results, as the outcome can determine the future revenue potential of a drug. For Novartis, the failure of del-desiran removes a potential growth driver from its pipeline, raising questions about the company's ability to offset upcoming patent expirations on some of its top-selling medicines.
Investors will be watching to see how Novartis management responds, whether through cost-cutting, acquisitions, or a renewed focus on other pipeline candidates. The company's shares had been under pressure even before this announcement, and today's decline adds to a challenging year for the stock.
What it means for investors
For everyday investors, the combination of rising oil prices and a major drug trial failure highlights two key risks in the market: inflation and company-specific setbacks.
On the inflation front, if oil prices continue to climb, it could delay interest rate cuts that many investors are hoping for. Higher rates tend to weigh on stock valuations, particularly for growth-oriented companies. Conversely, energy companies and sectors that benefit from higher oil prices, such as oil producers and service providers, may see their shares rise.
For those holding European equities through index funds or ETFs, the STOXX 600's modest decline is a reminder that broad market moves can be driven by a few large components. The Novartis drop, for instance, had an outsized impact on the index given its size.
Diversification remains a key strategy. While a single stock like Novartis can suffer a sharp loss, a well-diversified portfolio can cushion the blow. Similarly, having exposure to different asset classes, including commodities and bonds, can help manage the risks associated with inflation.
Looking ahead, investors will be closely monitoring oil price movements and any further geopolitical developments in the Gulf. Central bank communications will also be in focus, as policymakers weigh the latest inflation data against growth concerns. For now, the market's mood is cautious, with energy costs and healthcare disappointments casting a shadow over European equities.
Related reading: Novartis trial setback drags Swiss stocks and gold edges up as dollar slips.
